J. B. Chemicals & Pharmaceuticals Limited
NSE: JBCHEPHARM BSE: JBCHEPHARM
NSE
1,682.30
-24.10 (-1.41%)
Prev Close
1706.4
Open Price
1717
Volume
161,890
Today Low / High
1678.1 / 1717
52 WK Low / High
1385.75 / 1984
Range
1,598 - 1,766
BSE
1,680.15
-25.85 (-1.52%)
Prev Close
1706
Open Price
1710
Volume
1,916
Today Low / High
1678.5 / 1712
52 WK Low / High
1303 / 1998
Range
1,596 - 1,764
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1682.3 (target range: 1,598 - 1,766), reflecting a change of -24.1 (-1.41233%). On the BSE, it is listed at 1680.15 (target range: 1,596 - 1,764), showing a change of -25.85 (-1.51524%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
30 Oct
1,699.80
0.37%
29 Oct
1,686.00
0.65%
28 Oct
1,701.00
-0.88%
27 Oct
1,710.00
-0.51%
24 Oct
1,721.50
-1.12%
23 Oct
1,703.30
0.32%
21 Oct
1,682.10
0.52%
20 Oct
1,709.00
-1.04%
17 Oct
1,670.30
1.38%
16 Oct
1,667.50
0.23%
15 Oct
1,655.90
0.70%
14 Oct
1,668.00
-0.53%
13 Oct
1,665.00
-0.29%
10 Oct
1,673.60
-0.02%
09 Oct
1,684.80
-0.66%
08 Oct
1,657.30
1.20%
07 Oct
1,660.00
-0.20%
06 Oct
1,659.00
-0.01%
03 Oct
1,690.00
-1.28%
J. B. Chemicals & Pharmaceuticals Limited Graph
J. B. Chemicals & Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for J. B. Chemicals & Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,682.30, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,680.15 | 1,696.95 | 1,527.26 - 1,866.65 |
| 1,713.75 | 1,371.00 - 2,056.50 | ||
| 1,730.55 | 1,211.39 - 2,249.72 | ||
| Bearish Scenario | 1,680.15 | 1,663.35 | 1,497.01 - 1,829.68 |
| 1,646.55 | 1,317.24 - 1,975.86 | ||
| 1,629.75 | 1,140.82 - 2,118.67 |
Overview of J. B. Chemicals & Pharmaceuticals Limited
ISIN
INE572A01036
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
145,102
Market Cap
267,168,843,358
Last Dividend
15.5
Official Website
IPO Date
2002-07-01
DCF Diff
-1,610.06
DCF
3,308
Financial Ratios Every Investor Needs
Stock Dividend of JBCHEPHARM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-30 | July 30, 25 | 7 | 7 | 2025-07-30 | 2025-08-13 | |
| 2025-02-07 | February 07, 25 | 8.5 | 8.5 | 2025-02-08 | 2025-02-21 | |
| 2024-08-14 | August 14, 24 | 6.75 | 6.75 | 2024-08-14 | 2024-09-20 | |
| 2024-02-16 | February 16, 24 | 5.5 | 5.5 | 2024-02-16 | 2024-03-07 | |
| 2023-08-17 | August 17, 23 | 4.625 | 9.25 | 2023-08-17 | 2023-09-23 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 3,917.99 Cr | 1,316.55 Cr | 2,601.44 Cr | 0.6640 | 44.84 Cr | 36.25 Cr | 1,913.83 Cr | 659.58 Cr | 42.45 | 1,031.84 Cr | 0.1683 |
| 2024-03-31 | 3,484.18 Cr | 2,121.75 Cr | 1,345.88 Cr | 0.3863 | 30.56 Cr | 603.43 Cr | 754.16 Cr | 552.63 Cr | 35.66 | 933.48 Cr | 0.1586 |
| 2023-03-31 | 3,116.51 Cr | 2,015.49 Cr | 1,114.44 Cr | 0.3576 | 31.93 Cr | 547.04 Cr | 584.51 Cr | 409.84 Cr | 26.50 | 704.37 Cr | 0.1315 |
| 2022-03-31 | 2,424.24 Cr | 863.37 Cr | 1,560.87 Cr | 0.6439 | 29.11 Cr | 441.28 Cr | 460.48 Cr | 385.36 Cr | 24.93 | 581.53 Cr | 0.1590 |
| 2021-03-31 | 2,005.85 Cr | 717.44 Cr | 1,288.41 Cr | 0.6423 | 23.53 Cr | 341.95 Cr | 455.67 Cr | 447.96 Cr | 28.98 | 672.26 Cr | 0.2233 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 129.45 Cr | 4,273.78 Cr | 840.46 Cr | 3,433.3200 Cr | 27.89 Cr | -101.56 Cr | 528.95 Cr | 656.64 Cr | 10.32 Cr | 1.90 Cr | 27.98 Cr | 632.3300 Cr |
| 2024-03-31 | 88.22 Cr | 3,994.13 Cr | 1,070.80 Cr | 2,923.3300 Cr | 377.66 Cr | 289.44 Cr | 502.51 Cr | 634.88 Cr | 12.99 Cr | 1.70 Cr | 29.09 Cr | 868.2261 Cr |
| 2023-03-31 | 76.93 Cr | 3,553.87 Cr | 1,073.52 Cr | 2,480.3500 Cr | 572.45 Cr | 495.52 Cr | 430.49 Cr | 576.42 Cr | 118.25 Cr | 2.49 Cr | 28.09 Cr | 554.4500 Cr |
| 2022-03-31 | 56.54 Cr | 2,607.40 Cr | 468.79 Cr | 2,134.1230 Cr | 54.56 Cr | -1.99 Cr | 409.96 Cr | 566.82 Cr | 116.47 Cr | 3.17 Cr | 12.72 Cr | 383.7156 Cr |
| 2021-03-31 | 28.69 Cr | 2,238.12 Cr | 424.69 Cr | 1,809.7248 Cr | 44.99 Cr | 16.30 Cr | 347.45 Cr | 569.66 Cr | 108.56 Cr | 4.93 Cr | -651.88 Cr | 345.2737 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 902.4500 Cr | -295.8900 Cr | -579.6800 Cr | 804.8600 Cr | 26.8700 Cr | 115.0900 Cr | -97.5900 Cr | 659.5800 Cr | -343.9200 Cr | -237.0400 Cr | -26.4400 Cr |
| 2024-03-31 | 800.6117 Cr | -407.9074 Cr | -341.2720 Cr | 539.2447 Cr | 11.0507 Cr | 88.2151 Cr | -126.1128 Cr | 552.6278 Cr | -191.5957 Cr | -156.9875 Cr | -72.0300 Cr |
| 2023-03-31 | 625.6100 Cr | -961.7900 Cr | 356.5400 Cr | -139.3400 Cr | 20.3900 Cr | 76.9300 Cr | -764.9500 Cr | 555.2300 Cr | 523.1596 Cr | -127.5926 Cr | -20.5200 Cr |
| 2022-03-31 | 170.1345 Cr | 2.3199 Cr | -138.3851 Cr | -536.6547 Cr | 34.0703 Cr | 56.5441 Cr | -706.7892 Cr | 504.9020 Cr | -0.3273 Cr | -127.5628 Cr | -62.5143 Cr |
| 2021-03-31 | 314.7849 Cr | -230.6758 Cr | -87.4228 Cr | 267.0119 Cr | -3.2782 Cr | 22.4737 Cr | -47.7730 Cr | 596.8854 Cr | 0.3223 Cr | -73.2403 Cr | -70.0857 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 1,093.94 Cr | 584.09 Cr | 509.85 Cr | 0.4661 | 258.17 Cr | 202.38 Cr | 12.97 | 315.42 Cr | 0.1850 |
| 2025-03-31 | 949.48 Cr | 321.64 Cr | 627.84 Cr | 0.6612 | 1,233.03 Cr | 145.69 Cr | 9.36 | 222.76 Cr | 0.1534 |
| 2024-12-31 | 963.49 Cr | 316.74 Cr | 646.75 Cr | 0.6713 | 212.57 Cr | 162.49 Cr | 10.46 | 262.51 Cr | 0.1686 |
| 2024-09-30 | 1,000.62 Cr | 550.87 Cr | 449.75 Cr | 0.4495 | 228.64 Cr | 174.57 Cr | 11.24 | 280.47 Cr | 0.1745 |
| 2024-06-30 | 1,004.40 Cr | 547.44 Cr | 456.96 Cr | 0.4550 | 239.59 Cr | 176.83 Cr | 11.39 | 286.26 Cr | 0.1761 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 450.09 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -3,433.32 Cr |
| 2025-03-31 | 129.45 Cr | 335.00 Cr | 446.56 Cr | 815.38 Cr | 528.95 Cr | 1,922.74 Cr | 656.64 Cr | 4,273.78 Cr | 840.46 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 416.86 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -3,212.23 Cr |
| 2024-09-30 | 97.46 Cr | 319.40 Cr | 416.86 Cr | 817.14 Cr | 543.67 Cr | 1,913.30 Cr | 641.67 Cr | 4,029.41 Cr | 817.18 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 459.64 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,923.33 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 202.38 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 145.69 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 162.49 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 174.57 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 176.83 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2023-09-18 | September 18, 23 | 2:1 |
| 2005-04-05 | April 05, 05 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,690.70 | ₹4,056,549,508,373.00 | ₹1,560,907.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,738.00 | ₹1,788,732,898,056.00 | ₹507,645.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,560.10 | ₹1,204,898,044,500.00 | ₹354,021.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,197.60 | ₹996,839,216,220.00 | ₹4,250,056.00 |
| Mankind Pharma Limited | MANKIND | ₹2,384.00 | ₹984,016,240,160.00 | ₹593,366.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹974.45 | ₹980,520,395,716.00 | ₹458,971.00 |
| Lupin Limited | LUPIN | ₹1,963.50 | ₹896,844,333,000.00 | ₹1,017,447.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,138.90 | ₹661,474,968,435.00 | ₹3,556,831.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,506.50 | ₹658,384,672,500.00 | ₹178,327.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,891.20 | ₹533,698,169,981.00 | ₹398,054.00 |
| Laurus Labs Limited | LAURUSLABS | ₹953.65 | ₹514,804,014,931.00 | ₹1,545,364.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,271.20 | ₹322,508,801,922.00 | ₹106,442.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,465.30 | ₹308,003,793,847.00 | ₹102,941.00 |
| Cohance Lifesciences Limited | COHANCE | ₹753.40 | ₹288,226,083,276.00 | ₹1,868,840.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,682.30 | ₹263,441,852,870.00 | ₹161,890.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,318.90 | ₹250,017,076,708.00 | ₹201,166.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,555.00 | ₹238,875,000,000.00 | ₹20,033.00 |
| Eris Lifesciences Limited | ERIS | ₹1,591.70 | ₹216,811,113,902.00 | ₹40,393.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹16,473.00 | ₹211,346,761,497.00 | ₹44,604.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,281.50 | ₹208,224,272,482.00 | ₹289,135.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹897.40 | ₹176,395,747,478.00 | ₹69,233.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,101.00 | ₹174,564,413,184.00 | ₹543,954.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,032.80 | ₹154,516,575,629.00 | ₹43,860.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹819.90 | ₹146,852,182,413.00 | ₹412,467.00 |
| Granules India Limited | GRANULES | ₹565.60 | ₹137,253,425,770.00 | ₹384,397.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹904.45 | ₹110,959,145,199.00 | ₹27,710.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,152.00 | ₹102,119,398,064.00 | ₹17,413.00 |
| Strides Pharma Science Limited | STAR | ₹934.70 | ₹86,153,835,776.00 | ₹9,219,602.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹851.95 | ₹77,214,757,940.00 | ₹105,286.00 |
| FDC Limited | FDC | ₹460.65 | ₹74,998,465,195.00 | ₹252,540.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹460.75 | ₹70,541,773,224.00 | ₹53,334.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹352.85 | ₹69,011,043,776.00 | ₹149,611.00 |
| Sequent Scientific Limited | SEQUENT | ₹214.61 | ₹53,633,796,524.00 | ₹1,034,635.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹465.10 | ₹50,679,744,752.00 | ₹51,856.00 |
| Innova Captab Limited | INNOVACAP | ₹831.10 | ₹47,559,638,492.00 | ₹13,222.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹491.10 | ₹44,822,697,000.00 | ₹54,690.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹135.19 | ₹43,872,073,482.00 | ₹196,488.00 |
| Suven Life Sciences Limited | SUVEN | ₹197.55 | ₹43,073,939,692.00 | ₹121,404.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,403.90 | ₹39,758,138,159.00 | ₹6,281.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹726.30 | ₹36,837,285,962.00 | ₹86,074.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹470.95 | ₹33,157,587,963.00 | ₹3,282.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹325.40 | ₹32,631,927,452.00 | ₹54,623.00 |
Key Executives
Executive Vice President of Operations of Daman
Mr. Parmeshwar B. Bang
Gender: male
Year Born: 1968
Vice President of Legal
Mr. Himanshu Ranvah
Gender: male
Year Born: 1985
Vice President of Finance & Accounts
Mr. Bhagwat Singh Deora
Gender: male
Year Born: 1982
Vice President of Information & Technology
Mr. Suresh Bhise
Gender: male
Year Born: 1966
Vice President of HR & Administration
Mr. Sridhar Bharadwaj
Gender: male
Year Born: 1967
Chief Financial Officer
Mr. Narayan Saraf
Gender: male
Year Born: 1980
Assistant Vice President Human Resource
Suresh Amin
Gender: Not Specified
Year Born:
President of Operations
Mr. Kunal Khanna
Gender: male
Year Born: 1980
President of Global Business
Mr. Pradeep Kumar Singh
Gender: male
Year Born: 1964
Chief Executive Officer & Whole-Time Director
Mr. Nikhil Ashokkumar Chopra
Gender: male
Year Born: 1973
FAQs about J. B. Chemicals & Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Nikhil Ashokkumar Chopra.
What is the current market price of the stock?
The current price is ₹1,706.10.
What is the 52-week price range?
The range is ₹1385.75-1984.
What is the market capitalization of the company?
The market capitalization is ₹26,716.88 crores.
What is the dividend yield?
The dividend yield is 0.91%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 38.86.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of J. B. Chemicals & Pharmaceuticals Limited (ISIN: INE572A01036) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹26,716.88 crores and an average daily volume of 145,102 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹15.5.